Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | LY3410738 |
Synonyms | |
Therapy Description |
LY3410738 is a covalent inhibitor of mutant IDH1, which may lead to anti-tumor activity in IDH1-mutant tumors (PMID: 36056177). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3410738 | LY-3410738|LY 3410738 | IDH1 Inhibitor 8 | LY3410738 is a covalent inhibitor of mutant IDH1, which may lead to anti-tumor activity in IDH1-mutant tumors (PMID: 36056177). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H IDH1 D279N | acute myeloid leukemia | sensitive | LY3410738 | Preclinical - Cell culture | Actionable | In a preclinical study, LY3410738 inhibited (R)-2-hydroxyglutarate (R-2HG) production and cytokine-independent growth in an acute myeloid leukemia cell line expressing IDH1 R132H and D279N in culture (PMID: 36056177). | 36056177 |
IDH1 mutant | acute myeloid leukemia | predicted - sensitive | LY3410738 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, LY3410738 reversed mutant IDH1-induced differentiation block in patient-derived acute myeloid leukemia (AML) cells, inhibited 2-HG production, induced differentiation, and eliminated AML cells in patient-derived orthotopic animal models of IDH1-mutant AML (AACR 2019 Annual Meeting, Abstract LB-274). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04603001 | Phase I | LY3410738 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Recruiting | USA | FRA | ESP | DEU | CAN | BEL | 6 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Recruiting | USA | FRA | ESP | 6 |